Skip to main content
ANAB logo

AnaptysBio, Inc.

ANABNASDAQHealthcareBiotechnology

$48.73Today:- (-)1Y +41.47%

As of Oct 23, 2026 close

Market cap
$1.75B
P/E (TTM)
8.96
Forward P/E
-
Dividend yield
-
52-week range
$30.27$73.30
Volume (live)
-
Avg. volume (3M)
564.18K

AnaptysBio (ANAB) Stock Price & Financial Analysis

AnaptysBio Stock Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Price & Trading Activity
Day's Range$47.05 - $48.89
52-Week High$73.30
52-Week Low$30.27
Open$48.19
Volume (last close)467.47K
Average Volume (3M)564.18K
Earnings & Profitability
Revenue (TTM)188.78M
Net Income (TTM)195.72M
Free Cash Flow (TTM)18.07M
EPS (TTM)$6.26
Profit Margin103.68%
Operating Margin70.94%
Return on Equity (ROE)1849.06%
Debt to Equity25.47
Dividend Information
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%
Size & Valuation
Market Cap1.75B
Shares Outstanding35.98M
P/E Ratio (TTM)8.96
Price to Sales (P/S)9.29
Price to Book (P/B)165.62
EV/EBITDA27.45
Technical Indicators
50-Day MA$53.23
200-Day MA$56.38
1-Year Change+41.47%

Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology

Compare ANAB with other stocks

AnaptysBio at a Glance

As of the Oct 23, 2026 close, AnaptysBio (ANAB) has a market capitalization of $1.75B. The stock trades at 9.0× trailing earnings and 9.3× sales. Over the trailing twelve months it earned $195.72M on revenue of $188.78M (a 103.7% profit margin) and generated $18.07M of free cash flow. Revenue grew 27.0% year over year.

As of its latest reported balance sheet, it holds $133.83M in cash and securities against $269.59M of debt, a net debt position of $135.76M.

AnaptysBio does not currently pay a dividend.

The share price is up 41.5% over the past year. At $48.73 (the Oct 23, 2026 close) it sits within its 52-week range of $30.27 to $73.30, below its 200-day moving average of $56.38.

Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $77.40, 58.8% above the Oct 23, 2026 close.

Frequently Asked Questions About AnaptysBio

What is the current stock price for ANAB?

As of the Oct 23, 2026 close, ANAB stock trades at $48.73. The 52-week range is $30.27–$73.30, with a day range of $47.05–$48.89.

What is the P/E ratio for ANAB?

As of the Oct 23, 2026 close, AnaptysBio's trailing twelve-month (TTM) P/E ratio is 9.0, meaning investors pay $9.0 for every $1 of annual earnings. AnaptysBio operates in the Healthcare sector.

Does ANAB pay dividends?

AnaptysBio does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.

What do analysts recommend for ANAB?

Based on ratings from 6 professional analysts over the last 90 days, the consensus for ANAB is Buy. The average 12-month price target is $77.40, a 58.8% upside from the Oct 23, 2026 close of $48.73.

What is the market cap of ANAB?

As of the Oct 23, 2026 close, AnaptysBio's market capitalization is $1.75B, classifying it as a small-cap company. AnaptysBio operates in the Healthcare sector within the Biotechnology industry.